Aclarion Announces Pricing of $3.0 Million Public Offering
26 févr. 2024 09h15 HE
|
Aclarion, Inc.
BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
05 févr. 2024 08h00 HE
|
Aclarion, Inc.
Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical...
Aclarion Expands Nociscan Access Into Phoenix With Key Opinion Leader Surgeon Advisor Juan Uribe, MD
22 janv. 2024 08h00 HE
|
Aclarion, Inc.
Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute Dr. Uribe Becomes...
Aclarion Announces Updated Product Release That Expands MRI Scanner Access for Nociscan Solution
17 janv. 2024 08h00 HE
|
Aclarion, Inc.
Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine This new product release expands accessibility of Nociscan on the worldwide MR market Builds...
Aclarion and ATEC Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan
08 janv. 2024 08h00 HE
|
Aclarion, Inc.
Partnership aims to include Aclarion’s surgical decision support technology within ATEC’s AlphaInformatiX platform to better inform spine surgery Aclarion’s Nociscan is the first augmented...
Aclarion Announces Reverse Stock Split
02 janv. 2024 12h00 HE
|
Aclarion, Inc.
BROOMFIELD, CO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging...
Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams
27 nov. 2023 08h00 HE
|
Aclarion, Inc.
Pace of Nociscan orders accelerated 2.5x for the last 250 scans compared to the first 250 scans Further acceleration of scan volumes expected as MRIs are activated for the recently completed panel...
Aclarion Announces Achievement of Goal to Enroll 10 Leading Spine Surgery Key Opinion Leaders (KOLs) to Support Nociscan Adoption
08 nov. 2023 08h00 HE
|
Aclarion, Inc.
Recruitment of a panel of leading KOL surgeons who believe Nociscan can improve the diagnosis and treatment of discogenic low back pain is a critical step to establishing Nociscan as standard of care....
Aclarion Expands Immediate Nociscan Access Into New York City With Tenth Key Opinion Leader Surgeon Advisor Addition Roger Hartl, MD
06 nov. 2023 08h00 HE
|
Aclarion, Inc.
Dr. Hartl is the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at the Weill Cornell Brain and Spine Center in New York, and the co-director of New York-Presbyterian...
Aclarion Presents at the NIH HEAL Initiative Fall Meeting
01 nov. 2023 08h00 HE
|
Aclarion, Inc.
The Helping to End Addiction Long-term® Initiative, or NIH HEAL Initiative®, is funding ground-breaking low back pain research. The Back Pain Consortium (BACPAC) Research Program, a...